Psychedelic biotech sector equities (as measured by a basket of publicly traded psychedelic companies) will show negative or flat returns through Q4 2026 absent a concrete FDA approval or positive advisory committee vote for a psychedelic compound.

Publicly traded companies that develop psychedelic medicines will have negative or flat stock returns through the end of 2026 unless the FDA approves a psychedelic medicine or an FDA advisory committee votes to recommend approval. This matters because it signals whether investors believe these companies will succeed or whether the FDA rejection of MDMA has killed momentum.

Resolve date of 2026-06-16 is only ~1 month away, making this nearly immediately testable. The prediction covers 'through Q4 2026' but resolves in June — this is a structural inconsistency. Interpreting as: will the sector be underperforming as of June 2026 with no approval catalyst visible? That is plausible given FDA MDMA rejection precedent and ibogaine cardiac headwinds. However, the sector is small and volatile; individual company news can move indices. The 'absent a concrete FDA approval catalyst' clause is essentially guaranteed to be true through June 2026, making the outcome dependent purely on market sentiment. Confidence modestly reduced due to short-term volatility risk and resolve date ambiguity.